These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9444999)

  • 1. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.
    Zolla-Pazner S; Lubeck M; Xu S; Burda S; Natuk RJ; Sinangil F; Steimer K; Gallo RC; Eichberg JW; Matthews T; Robert-Guroff M
    J Virol; 1998 Feb; 72(2):1052-9. PubMed ID: 9444999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
    Robert-Guroff M; Kaur H; Patterson LJ; Leno M; Conley AJ; McKenna PM; Markham PD; Richardson E; Aldrich K; Arora K; Murty L; Carter L; Zolla-Pazner S; Sinangil F
    J Virol; 1998 Dec; 72(12):10275-80. PubMed ID: 9811775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.
    Girard M; Meignier B; Barré-Sinoussi F; Kieny MP; Matthews T; Muchmore E; Nara PL; Wei Q; Rimsky L; Weinhold K
    J Virol; 1995 Oct; 69(10):6239-48. PubMed ID: 7666524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.
    Lubeck MD; Natuk R; Myagkikh M; Kalyan N; Aldrich K; Sinangil F; Alipanah S; Murthy SC; Chanda PK; Nigida SM; Markham PD; Zolla-Pazner S; Steimer K; Wade M; Reitz MS; Arthur LO; Mizutani S; Davis A; Hung PP; Gallo RC; Eichberg J; Robert-Guroff M
    Nat Med; 1997 Jun; 3(6):651-8. PubMed ID: 9176492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
    Berman PW; Murthy KK; Wrin T; Vennari JC; Cobb EK; Eastman DJ; Champe M; Nakamura GR; Davison D; Powell MF; Bussiere J; Francis DP; Matthews T; Gregory TJ; Obijeski JF
    J Infect Dis; 1996 Jan; 173(1):52-9. PubMed ID: 8537682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
    J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
    VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
    J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
    Clements-Mann ML; Weinhold K; Matthews TJ; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Hsieh RH; Mestecky J; Zolla-Pazner S; Mascola J; Schwartz D; Siliciano R; Corey L; Wright PF; Belshe R; Dolin R; Jackson S; Xu S; Fast P; Walker MC; Stablein D; Excler JL; Tartaglia J; Paoletti E
    J Infect Dis; 1998 May; 177(5):1230-46. PubMed ID: 9593008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.
    Menon V; Ayala VI; Rangaswamy SP; Kalisz I; Whitney S; Galmin L; Ashraf A; LaBranche C; Montefiori D; Petrovsky N; Kalyanaraman VS; Pal R
    J Gen Virol; 2017 Aug; 98(8):2143-2155. PubMed ID: 28758637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
    Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.
    el-Amad Z; Murthy KK; Higgins K; Cobb EK; Haigwood NL; Levy JA; Steimer KS
    AIDS; 1995 Dec; 9(12):1313-22. PubMed ID: 8605050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.